These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3890700)

  • 61. The antiparkinsonian efficacy of bromocriptine.
    Lieberman A; Zolfaghari M; Boal D; Hassouri H; Vogel B; Battista A; Fuxe K; Goldstein M
    Neurology; 1976 May; 26(5):405-9. PubMed ID: 817221
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prescribing in Parkinson's disease: a story of hope and adverse events.
    Morrish P
    Pract Neurol; 2012 Oct; 12(5):335-40. PubMed ID: 22976066
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Experiences with a new ergoline (CF 25-397) in parkinsonism.
    Teychenne PF; Pfeiffer R; Bern SM; Calne DB
    Neurology; 1977 Dec; 27(12):1140-3. PubMed ID: 563012
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Treatment of Parkinson disease with Bromocriptine (CB 154 Sandoz) (author's transl)].
    Jacobides GB; Audibert A
    Ther Umsch; 1975 Jul; 32(7):469-71. PubMed ID: 1105868
    [No Abstract]   [Full Text] [Related]  

  • 65. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mesulergine in early Parkinson's disease: a double blind controlled trial.
    Dupont E; Mikkelsen B; Jakobsen J
    J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):390-5. PubMed ID: 3517235
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cabergoline : a review of its use in the treatment of Parkinson's disease.
    Curran MP; Perry CM
    Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The pharmacology of mesulergine.
    Pfeiffer RF
    Clin Neuropharmacol; 1985; 8(1):64-72. PubMed ID: 3884151
    [No Abstract]   [Full Text] [Related]  

  • 71. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
    Pfeiffer RF; Wilken K; Glaeske C
    Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
    [TBL] [Abstract][Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.